Pemlimogene Merolisbac Uses, Dosage, Side Effects and more

Pemlimogene Merolisbac is under investigation in clinical trial NCT03371381 (An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung).

Trade Name Pemlimogene Merolisbac
Generic Pemlimogene merolisbac
Pemlimogene merolisbac Other Names Ladd listeria monocytogenes jnj-64041757, Live-attenuated listeria monocytogenes encoding egfrviii-mesothelin vaccine jnj-64041757, Pemlimogene merolisbac, Recombinant live-attenuated double-deleted (ladd) strain of listeria monocytogenes (lm .delta.acta/.delta.inlb) expressing a fusion protein comprising the n-terminal 100 amino acids of the lm acta protein (actan100), 5 tandem copies of a 21 amino acid fr
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Innovators Monograph


*** Taking medicines without doctor's advice can cause long-term problems.
Share